Brief: Statera Biopharma Announces First Patient Dosed In Study Of STAT-205 For Acute COVID
20/12/2021 21:23
Dec 20 (Reuters) - Statera Biopharma Inc STAB.O :
* STATERA BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN STUDY
OF
STAT-205 FOR ACUTE COVID
* STATERA BIOPHARMA INC - EXPECT STAT-205 PRELIMINARY TRIAL
RESULTS TO BE REPORTED IN 2022
Source text for Eikon: ID:nGNX8jVpQL
Further company coverage: STAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc